Trial Profile
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Vitespen
- Indications Gastrointestinal stromal tumours; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms PEMBROSARC
- 01 Jun 2022 Primary endpoint has been met (Assessment of the efficacy of MK3475 associated with Metronomic Cyclophosphamide and G100 per RECIST v1.1 criteria) , according to Results published in the Nature Medicine
- 01 Jun 2022 Results (n=30) reporting efficacy and safety data from a cohort enrolling patients selected based on presence of tertiary lymphoid structures published in the Nature Medicine
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology